Loading
Dositinib is an experimental small molecule from Henan Genuine Biotech, in phase 2 trials for EGFR-mutant non-small cell lung cancer.
Dositinib (90-1408, 哆希替尼) is a small molecule (oral EGFR tyrosine kinase inhibitor) from Henan Genuine Biotech. An EGFR tyrosine kinase inhibitor taken as a tablet. Its furthest stage is phase 2, for EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1/2 NCT07231068 in EGFR-mutant NSCLC recruiting (started October 2022); also in NCT07362940 with GEN-725. Whether it works in people has not been established unless a trial below reports it.
An EGFR tyrosine kinase inhibitor taken as a tablet. Connects to EGFR.
1.Dositinib slips into a pocket on EGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Dositinib" OR ABSTRACT:"Dositinib" OR TITLE:"90-1408" OR ABSTRACT:"90-1408" OR TITLE:"哆希替尼" OR ABSTRACT:"哆希替尼") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Dositinib, not a curated reading list.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/